Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
boston blog main
life sciences
national blog main
new york blog main
boston top stories
national top stories
new york top stories
san diego blog main
san francisco blog main
alirocumab
boston
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
drugs
gene therapy
generic drugs
indiana blog main
indiana top stories
medicare
national
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
san diego top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alex azar
alnylam pharmaceuticals
american patients first
amgen
astellas pharma
What
drug
5
×
long
5
×
awaited
data
details
house
lower
medicines
plan
prices
afternoon
ago
alnylam
anathema
anticipated
based
biotech
biotechs
blueprint
cholesterol
considering
cost
cut
democrat
diseases
driving
drugs
dyne
early
elements
evidence
expected
experimental
eyes
genetic
good
having
healthcare
heart
history
Language
unset
Current search:
long
×
drug
×
biotech
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details
